# Safety and Efficacy of Autologous Human Schwann Cell (ahSC) Augmentation in Severe Peripheral Nerve Injury (PNI)

> **NCT05541250** · PHASE1 · RECRUITING · sponsor: **W. Dalton Dietrich** · enrollment: 30 (estimated)

## Conditions studied

- Peripheral Nerve Injury

## Interventions

- **BIOLOGICAL:** Autologous Human Schwann Cell

## Key facts

- **NCT ID:** NCT05541250
- **Lead sponsor:** W. Dalton Dietrich
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-04
- **Primary completion:** 2026-09-29
- **Final completion:** 2026-09-29
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-09-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05541250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05541250, "Safety and Efficacy of Autologous Human Schwann Cell (ahSC) Augmentation in Severe Peripheral Nerve Injury (PNI)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05541250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*